Theravance Biopharma reports Q3 EPS (26c), consensus (23c)

Reports Q3 revenue $16.9M, consensus $15.34M. Cash, cash equivalents and marketable securities totaled $91.4M as of September 30. Rick Winningham, Theravance Biopharma (TBPH) CEO commented, “Through our collaboration with Viatris, we achieved a strong quarter for YUPELRI demand and made progress on recent mix-related pricing headwinds, therein driving quarterly net sales to an all-time high. We believe we are well positioned to build on recent momentum and achieve continued YUPELRI growth, while continuing to pay careful attention to our cost structure.” He continued, “In addition, we are pleased with the progress we made in CYPRESS this quarter and reaffirm our development timelines with a goal of making this important therapy available to patients.”